American Shared Hospital Services Shares Developments at Mevion Medical Systems
September 24 2013 - 8:03AM
Business Wire
AMERICAN SHARED HOSPITAL SERVICES (NYSE MKT:AMS), a
leading provider of turnkey technology solutions for advanced
radiosurgical and radiation therapy services, today shared a recent
announcement from Mevion Medical Systems, developer of the MEVION
S250 Proton Therapy System for cancer treatment. AMS owns an equity
interest in Mevion, and will supply a MEVION S250 for the proton
center now under construction at MD Anderson Cancer Center in
Orlando, in addition to other projects under development:
MEVION S250 at the Siteman Cancer Center at
Barnes-Jewish Hospital and Washington University School of Medicine
Moves to Clinical Commissioning
Littleton, MA, September 22nd, 2013 -- Today, Mevion Medical
Systems announced moving from acceptance testing to the clinical
commissioning phase of its MEVION S250 Proton Therapy System
installed at the S. Lee Kling Center for Proton Therapy at the
Siteman Cancer Center at Barnes-Jewish Hospital and Washington
University School of Medicine in St. Louis, MO. The MEVION S250 is
a unique proton therapy device designed to deliver the same
precise, non-invasive treatment capabilities and advantages of
conventional systems but with a significantly reduced size,
improved reliability, efficient clinical workflow and lower
implementation and operational costs. This important milestone
marks the handover and operational control of the first MEVION S250
to the physics and radiation oncology proton teams from the Siteman
Cancer Center at Barnes-Jewish Hospital and Washington University
School of Medicine for clinical commissioning and patient
treatment.
Acceptance testing is a series of demanding tests designed to
independently put the MEVION S250 through its paces, carefully
validating that technical and clinical performance specifications
are met and that the system is ready for clinical commissioning.
The Washington University physics team led by Eric E. Klein, PhD,
chief of proton therapy physics, performed these tests over a
three-month period. "The results of our testing confirm that the
MEVION S250 is ready to move into the clinical commissioning
phase," said Dr. Klein. "We are excited to be in final clinical
preparation for our first patient treatment later this year," added
Jeffrey D. Bradley, MD, Washington University radiation oncologist
and director of the S. Lee Kling Center for Proton Therapy.
The MEVION S250 proton therapy system at the Siteman Cancer
Center is the first of many Mevion single room systems to come
on-line in the United States. "The MEVION S250 has forever changed
the economics and accessibility of proton therapy, delivering the
only modern, advanced and practical proton therapy solution with a
footprint similar to a conventional radiation therapy vault such
that it can be integrated within any cancer center," said Joseph K.
Jachinowski, chief executive officer of Mevion Medical Systems. Two
additional MEVION S250 proton therapy systems have been delivered
and are under installation at Robert Wood Johnson University
Hospital in New Brunswick, NJ, and at the Stephenson Cancer Center
at Oklahoma University in Oklahoma City, OK, with clinical start
scheduled for next year. A fourth center at First Coast Oncology in
Jacksonville, FL, has completed the facility construction and is
already under installation with major gantry components already
installed. The MEVION S250 at the MD Anderson Cancer Center in
Orlando is under construction and will be completed and ready for
system components installation early next year. In addition,
University Hospitals in Cleveland, OH just held their
groundbreaking ceremony to commence construction of their new
proton therapy center.
Mevion is showcasing the MEVION S250 and educating clinicians
about the benefits of Practical Proton Therapy at the 55th Annual
Meeting of the American Society for Radiation Oncology (ASTRO) in
Atlanta, GA from September 22nd to the 24th.
About Mevion Medical Systems
Mevion Medical Systems, Inc. is a radiation therapy company
dedicated to advancing the treatment of cancer. As the pioneering
developer of modern proton therapy systems, Mevion provides
innovative, safe, and effective solutions by transforming advances
in medical technology and science into practical clinical
reality.
Mevion's flagship product, the MEVION S250 Proton Therapy
System, is designed to preserve all of the treatment benefits of
traditional proton therapy systems while removing the obstacles of
size, cost and complexity. Realizing this vision, Mevion has
forever changed the economics and accessibility of proton therapy
worldwide.
Founded in 2004, Mevion is a privately held company
headquartered in the Boston metropolitan area with international
offices in the United Kingdom and Japan.
Visit us at: www.mevion.com.
About AMS
American Shared Hospital Services provides turnkey technology
solutions for advanced radiosurgical and radiation therapy
services. AMS is the world leader in providing Gamma Knife
radiosurgery equipment, a non-invasive treatment for malignant and
benign brain tumors, vascular malformations and trigeminal
neuralgia (facial pain). The Company also offers the latest IGRT
and IMRT systems, as well as its proprietary Operating Room for the
21st CenturySM concept. AMS owns common stock in Mevion Medical
Systems, Inc., developer of the compact MEVION S250 Proton Therapy
System.
Safe Harbor Statement
This press release may be deemed to contain certain
forward-looking statements with respect to the financial condition,
results of operations and future plans of American Shared Hospital
Services, which involve risks and uncertainties including, but not
limited to, the risks of the Gamma Knife and radiation therapy
businesses. Further information on potential factors that could
affect the financial condition, results of operations and future
plans of American Shared Hospital Services is included in the
filings of the Company with the Securities and Exchange Commission,
including the Company's Annual Report on Form 10-K for the year
ended December 31, 2012, the Quarterly Report on Form 10-Q for the
quarters ended on March 31, 2013 and June 30, 2013, and the
definitive Proxy Statement for the Annual Meeting of Shareholders
held on June 11, 2013.
American Shared Hospital ServicesErnest A. Bates, M.D.,
415-788-5300Chairman and Chief Executive
Officere.bates@ashs.comorBerkman AssociatesNeil Berkman,
310-477-3118Presidentinfo@berkmanassociates.com
American Shared Hospital... (AMEX:AMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
American Shared Hospital... (AMEX:AMS)
Historical Stock Chart
From Apr 2023 to Apr 2024